Rational design of highly potent HIV-1 fusion inhibitory proteins: Implication for developing antiviral therapeutics
- 1 July 2005
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 332 (3) , 831-836
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domainBiochemical and Biophysical Research Communications, 2005
- Enfuvirtide: a new class of antiretroviral therapy for HIV infectionOral Diseases, 2004
- Design and Properties of NCCG-gp41, a Chimeric gp41 Molecule with Nanomolar HIV Fusion Inhibitory ActivityJournal of Biological Chemistry, 2001
- Mechanisms of Viral Membrane Fusion and Its InhibitionAnnual Review of Biochemistry, 2001
- Protein Design of an HIV-1 Entry InhibitorScience, 2001
- Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformationJournal of Molecular Biology, 2000
- Atomic structure of the ectodomain from HIV-1 gp41Nature, 1997
- A trimeric structural domain of the HIV-1 transmembrane glycoproteinNature Structural & Molecular Biology, 1995
- Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.Proceedings of the National Academy of Sciences, 1994
- HIV-1 inhibition by a peptideNature, 1993